Johnson & Johnson: HIV Vaccine Candidate Fails To Provide Protection; To Discontinue Imbokodo Study

Johnson & Johnson (JNJ) said results from the primary analysis of a phase 2b vaccine clinical trial showed the investigational HIV vaccine regimen did not provide sufficient protection against the infection. This proof-of-concept efficacy study, also known as the Imbokodo study, began in 2017, and completed vaccinations in 2020. It included approximately 2,600 young women across five countries in sub-Saharan Africa. Johnson & Johnson said, based on the results, the Imbokodo study will not continue.

Johnson & Johnson noted that the phase 3 Mosaico study which is testing the safety and efficacy of a different composition of the HIV vaccine regimen among men who have sex with men and transgender individuals will continue.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bobo's recalled one lot of Bobo's 4-pack Almond Butter Protein Bars for potentially containing undeclared peanuts, the U.S. Food and Drug Administration or FDA said in a statement. The recall was initiated after it was discovered that product containing peanuts was distributed in packaging that did not reveal the presence of peanuts on the ingredient deck. Birmingham, Michigan-based RFA Brands LLC, d/b/a myCharge is recalling about 67,000 units of myCharge powerbanks citing fire and burn risks, the U.S. Consumer Product Safety Commission said. The recall was initiated after myCharge received 30 reports of the powerbanks overheating, resulting in seven injuries as well as property damage to household flooring, walls and furniture. Comcast Corp. (CMCSA, CMCSK) on Thursday reported that profit for the third quarter doubled from last year, driven by 19 percent revenue growth amid significant growth across each of its businesses. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend.
Follow RTT